The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
Amazon and Blue Origin founder Jeff Bezos gave more insight into his space company's lunar plans on Wednesday.Technologyread more
As the presidents of U.S. and China near a highly anticipated meeting on trade, the gap in both sides' expectations regarding a deal remains wide.World Politicsread more
Delta warned travelers that a technical problem could delay flights on Wednesday.Airlinesread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
If the Trump administration and Congress fail to reach a spending agreement, the White House will offer to keep the government funded at its current levels for a year, Mnuchin...Politicsread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
Investors need to be cautious because the economy will get hurt the longer the trade war drags on, Jim Cramer says.Mad Money with Jim Cramerread more
Slack Technologies' reference price was set at $26 per share, the New York Stock Exchange announced Wednesday evening.Technologyread more
Amazon will not use pharmacy licenses it obtained from Tennessee and Indiana to sell prescriptions, but will use them to sell medical devices and supplies instead, the company has told regulators.
Analysts from the investment firm Jefferies uncovered correspondence between the company and regulators in Tennessee and Indiana. Excerpts from these documents, which Jefferies obtained in a Freedom of Information Act request, show that Amazon intends to sell medical devices and supplies in its Indiana fulfillment center, but would not be storing or distributing prescription drugs.
"Applicant (Amazon) will not store or ship drugs," the application clearly states.
That said, most industry experts aren't ruling out the possibility of Amazon entering the prescription drug market. Instead, they maintain that it's a matter of if, not when.
"There has been a massive overreaction to the Amazon threat," said Adam Fein, president of Pembroke Consulting and a drug supply chain expert, to CNBC.
"I would never underestimate Amazon," he continued. "But I remain somewhat skeptical of Amazon's ability and desire to fundamentally alter the drug channel (as) the incumbents will have many opportunities to defend their position, capture value from internet technologies, and streamline distribution."
Jefferies analysts stress that Amazon could navigate the complexities of the prescription drug space, but that it will be likely to disrupt some lower-hanging fruit first. And that includes selling medical supplies, such as surgical equipment and devices. That would be a more immediate threat to medical distribution companies, like McKesson and Cardinal Health, rather than to pharmacies and pharmacy benefits managers.
Amazon is expected to make a decision about whether it will get into the prescription drug business in the coming weeks.